MONTERREY, Mexico / Jul 17, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or the “Company”), a Latin American healthcare company with operations in Mexico, Peru and Colombia, announced today the launch of the first oncology insurance in Mexico, fully integrated through its hospital network in Monterrey, Nuevo Leon.
Auna's integrated oncological insurance addresses the unmet needs of families and patients for cancer prevention, detection, and treatment coverage. The product, named after its successful predecessors in Peru, “OncoSalud”, covers the latest medical guidelines and protocols, as well as technology, within its Monterrey hospital network. OncoSalud benefits from over 35 years of product experience in Peru alongside outstanding oncology research capabilities in Colombia that have resulted in first-world survivor rates for its cancer patients.
The insurance product is tailored for families with members aged 70 years and younger without pre-existing oncological conditions. OncoSalud has been attractively priced at USD 40 per month on average, and policyholders benefit from an annual insured amount of up to USD 0.5 million. OncoSalud is well regarded for its focus on prevention and early detection, thus preventive check-ups and related diagnostic exams are free to policyholders.
“We are thrilled to reach this milestone after over 35 years of developing our integrated insurance products and services in Peru and Colombia,” said Suso Zamora, Chairman of the Board and President of Auna. “Auna has become a very relevant player in high complexity oncology in the cities we serve, and we believe this new product is a natural extension of what we already offer which impacts so positively the families and patients we cover. We are certain we will transform access to oncology treatments for Mexican communities of patients and healthcare providers alike.” He further remarked: “We aim to provide healthcare accessibility in the region, and estimate the total addressable market for this insurance product in Mexico is up to 14 million people who would benefit from our research, treatment protocols and world-class medical capabilities.”
Sven Boes, Executive Vice President of Health Services added, “We are excited to launch our oncological protection insurance to the market, marking a significant milestone in our ongoing commitment to improving the lives of cancer patients and providing early-stage disease care. This product aims not only to alleviate physical symptoms but also to provide comprehensive support addressing the emotional and physical needs of patients during their cancer journey. Today we cover over a million with insurance products that are accessible and deliver best in class services. Last year, we treated over 40,000 cancer patients in the region.”
Auna aims to promote prevention and early detection through its innovative insurance product, underscoring its commitment to enhancing healthcare accessibility and transforming healthcare delivery across the region. With cancer ranking as Mexico's third leading cause of mortality, and a substantial portion of cases preventable or potentially diagnosable in time, this initiative seeks to empower individuals with proactive measures for better health outcomes.
About Auna
Auna is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America’s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of March 31, 2024, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.2 million healthcare plans.
For more information visit www.aunainvestors.com.
Forward Looking Statements
This press release contains forward-looking statements. The forward-looking statements contained herein include statements about the total addressable market for Auna’s insurance product in Mexico, among others. These expectations may or may not be realized. Some of these expectations may be based upon assumptions or judgments that prove to be incorrect. In addition, Auna’s business and operations involve numerous risks and uncertainties, many of which are beyond the control of Auna, which could result in Auna’s expectations not being realized or otherwise materially affect the financial condition, results of operations and cash flows of Auna. Among the risks and uncertainties that could cause actual results to differ from those described in forward-looking statements are if third-party or internally generated data prove to be inaccurate or Auna makes errors in its assumptions based on that data. Additional information relating to the uncertainties affecting Auna’s business is contained in its filings with the Securities and Exchange Commission. The forward-looking statements are made only as of the date hereof, and Auna does not undertake any obligation to and expressly disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date such statements were made, or to reflect the occurrence of unanticipated events.
Last Trade: | US$6.83 |
Daily Change: | 0.17 2.55 |
Daily Volume: | 10,282 |
Market Cap: | US$204.900M |
November 19, 2024 August 21, 2024 May 22, 2024 March 22, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB